ZTS vs IDXX Comparison: AI Score, Valuation, Performance and Upside
Compare Zoetis' animal health pharmaceuticals and vaccines against IDEXX's veterinary diagnostics and testing platform.
Use this Zoetis vs IDEXX Laboratories comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
IDXX holds the edge across 3 of 5 key metrics in this comparison. IDXX has delivered stronger 1-year price return (-15.55% vs -50.27%), though ZTS has the better forward P/E setup (11.84x vs 33.15x for IDXX). On fundamentals, IDXX is growing revenue faster (9.70%), while ZTS maintains the higher operating margin (40.72%) — a classic growth-versus-profitability split. Analyst consensus implies similar upside for both: +24.13% for ZTS and +25.93% for IDXX.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | ZTS | IDXX |
|---|---|---|
| AI scorei | 39.2 | 50.7 |
| AI ranki | #1232 | #490 |
| Latest closei | $75.81 | $535.38 |
| 1M returni | +1.91% | -8.45% |
| 6M returni | -37.98% | -13.50% |
| 1Y returni | -50.27% | -15.55% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ZTS | IDXX |
|---|---|---|
| 1Y ago | $4.95K (-50.5%) started 2025-09-04 | $8.36K (-16.4%) started 2025-09-04 |
| 5Y ago | $3.91K (-60.9%) started 2021-09-07 | $7.85K (-21.5%) started 2021-09-07 |
| 10Y ago | $16.88K (+68.8%) started 2016-09-06 | $46.98K (+369.8%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | ZTS | IDXX |
|---|---|---|
| Market capi | $31.96B | $43.72B |
| Trailing P/Ei | 12.62 | 39.06 |
| Forward P/Ei | 11.84 | 33.15 |
| Price/Salesi | 8.16 | 10.74 |
| EV/Revenuei | 4.15 | 9.80 |
| Analyst targeti | $96.00 | $698.92 |
| Target upsidei | +24.13% | +25.93% |
| Metric | ZTS | IDXX |
|---|---|---|
| Revenue growthi | -0.20% | 9.70% |
| Earnings growthi | 1.20% | 17.60% |
| EPS growthi | +1.20% | +17.60% |
| FCF margini | +21.18% | +19.97% |
| Operating margini | 40.72% | 34.98% |
| Profit margini | 27.68% | 25.03% |
| ROIC proxyi | 64.91% | 74.21% |
| Return on equityi | 64.91% | 74.21% |
| Dividend yieldi | 2.74% | N/A |
| Betai | 0.73 | 1.54 |
| Debt/equityi | 294.00 | 67.97 |
| Current ratioi | 3.08 | 1.17 |
| Quick ratioi | 1.57 | 0.73 |
Over the past year, ZTS and IDXX have moved moderately in the same direction (correlation of 0.42), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ZTS | IDXX |
|---|---|---|---|
| 1Y | Growthi | -50.52% | -16.40% |
| CAGRi | -50.57% | -16.43% | |
| Volatilityi | 37.51% | 32.10% | |
| Sharpe ratioi | -1.79 | -0.54 | |
| Sortino ratioi | -2.04 | -0.80 | |
| Max drawdowni | 53.13% | 31.34% | |
| Current drawdowni | 50.55% | 30.17% | |
| Avg drawdowni | 27.61% | 16.91% | |
| Ulcer Indexi | 32.33% | 19.93% | |
| Max daily dropi | 21.50% | 5.02% | |
| Max wkly dropi | 33.16% | 8.95% | |
| 5Y | Growthi | -62.26% | -21.46% |
| CAGRi | -17.73% | -4.72% | |
| Volatilityi | 29.46% | 35.69% | |
| Sharpe ratioi | -0.67 | -0.09 | |
| Sortino ratioi | -0.85 | -0.13 | |
| Max drawdowni | 69.95% | 52.79% | |
| Current drawdowni | 68.29% | 30.17% | |
| Avg drawdowni | 32.36% | 27.23% | |
| Ulcer Indexi | 35.44% | 29.77% | |
| Max daily dropi | 21.50% | 9.79% | |
| Max wkly dropi | 33.16% | 21.97% | |
| 10Y | Growthi | +57.78% | +369.84% |
| CAGRi | +4.67% | +16.74% | |
| Volatilityi | 27.42% | 33.00% | |
| Sharpe ratioi | 0.14 | 0.50 | |
| Sortino ratioi | 0.19 | 0.75 | |
| Max drawdowni | 69.95% | 54.00% | |
| Current drawdowni | 68.29% | 30.17% | |
| Avg drawdowni | 17.94% | 17.38% | |
| Ulcer Indexi | 25.34% | 22.87% | |
| Max daily dropi | 21.50% | 11.94% | |
| Max wkly dropi | 33.16% | 27.89% |
| Category | ZTS | IDXX |
|---|---|---|
| Company | ZTS | IDXX |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Diagnostics & Research |
| Core business | Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the an… | IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.